Immatics/BMY Deal 'Notable' for Immunocore Holdings (IMCR) - Jefferies

Jefferies analyst Michael Yee said the Immatics (IMTX)/Bristol Myers Squibb (BMY) collaboration, announced yesterday, is "notable" and provides additional validation for Immunocore Holdings (NASDAQ: IMCR).

The analyst reiterated a Buy rating and $65.00 price target on IMCR.

For an analyst ratings summary and ratings history on Immunocore Holdings click here. For more ratings news on Immunocore Holdings click here.

Shares of Immunocore Holdings closed at $29.74 yesterday.

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS